Company Overview: ENTA

Upcoming Projects (ENTA)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ENTA)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (ENTA)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (ENTA)

Enata Plans to Start Phase 1 Clinical Development for Respiratory Syncytial Virus (RSV) and Hepatitis B Virus (HBV) in Q4 2017
Ticker: ENTA
Occurred on: Jan 05, 2018
AbbVie/Enata Hepatitis C Drug, Glecaprevir/Pibrentasvir (G/P), PDUFA Approximately 8/2/2017
Tickers: ABBV, ENTA
Occurred on: Aug 03, 2017
AbbVie (ABBV) Announces Top-Line Data from Phase 3 CERTAIN-1 Study Evaluating Ribavirin-Free Regimen of Glecaprevir and Pibrentasvir (G/P) in Japanese Patients with Genotype 1 Chronic Hepatitis C virus (HCV) Infection Without Cirrhosis
Tickers: ABBV, ENTA
Occurred on: Jan 09, 2017
ABT-493 and ABT-530 Phase 3 Data to be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place November 11-15, 2016 in Boston
Ticker: ENTA
Occurred on: Nov 15, 2016
Enanta Pharmaceuticals (ENTA) Presents Data on a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV) at the 10th Annual Respiratory Syncytial Virus Conference
Ticker: ENTA
Occurred on: Sep 29, 2016
Enanta Pharmaceuticals (ENTA) Initiates Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)
Ticker: ENTA
Occurred on: Sep 28, 2016
PDUFA 2H 2016 for VIEKIRA PAK - once-daily, fixed-dose formulation for HCV - genotype - through Abbvie
Ticker: ENTA
Occurred on: Jul 25, 2016
Enanta Pharmaceuticals (ENTA) Enrolls Patients in Phase 3 Study of ABT-493 and ABT-530 in treating Pan-Genotypic Hepatitis C
Ticker: ENTA
Occurred on: Apr 15, 2016

Strategic Initiatives (ENTA)

Don’t see a strategic initiative related to the company you care about? Create your own!

ENTA Overview